AR035778A1 - Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil)etanol para tratar la incontinencia urinaria - Google Patents

Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil)etanol para tratar la incontinencia urinaria

Info

Publication number
AR035778A1
AR035778A1 ARP020100352A ARP020100352A AR035778A1 AR 035778 A1 AR035778 A1 AR 035778A1 AR P020100352 A ARP020100352 A AR P020100352A AR P020100352 A ARP020100352 A AR P020100352A AR 035778 A1 AR035778 A1 AR 035778A1
Authority
AR
Argentina
Prior art keywords
ethanol
amino
urinary incontinence
methanosulphonamidephenyl
hydroxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP020100352A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR035778A1 publication Critical patent/AR035778A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Medicamentos que contienen 2-amino-1(4-hidroxi-2-metanosulfonamidofenil)etanol, uno de sus dos isómeros ópticos y/o sus sales farmacológicamente aceptables, en particular para tratar la incontinencia urinaria.
ARP020100352A 2001-02-01 2002-02-01 Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil)etanol para tratar la incontinencia urinaria Suspension/Interruption AR035778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10104369A DE10104369A1 (de) 2001-02-01 2001-02-01 Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz

Publications (1)

Publication Number Publication Date
AR035778A1 true AR035778A1 (es) 2004-07-14

Family

ID=7672382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100352A Suspension/Interruption AR035778A1 (es) 2001-02-01 2002-02-01 Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil)etanol para tratar la incontinencia urinaria

Country Status (26)

Country Link
EP (1) EP1363614B1 (es)
JP (1) JP2004517158A (es)
KR (1) KR20030075173A (es)
CN (1) CN1489459A (es)
AR (1) AR035778A1 (es)
AT (1) ATE293966T1 (es)
BG (1) BG108033A (es)
BR (1) BR0206854A (es)
CA (1) CA2434565A1 (es)
CZ (1) CZ20032097A3 (es)
DE (2) DE10104369A1 (es)
DK (1) DK1363614T3 (es)
EA (1) EA200300789A1 (es)
EC (1) ECSP034684A (es)
EE (1) EE200300357A (es)
ES (1) ES2240708T3 (es)
HU (1) HUP0302752A2 (es)
IL (1) IL156730A0 (es)
MX (1) MXPA03006816A (es)
NO (1) NO20033428L (es)
PL (1) PL361731A1 (es)
PT (1) PT1363614E (es)
SK (1) SK9772003A3 (es)
UY (1) UY27145A1 (es)
WO (1) WO2002060421A2 (es)
ZA (1) ZA200305201B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
AU2014309012B2 (en) * 2013-08-19 2019-03-14 Taris Biomedical Llc Multi-unit drug delivery devices and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US341584A (en) * 1886-05-11 Device foe
FR148F (es) * 1962-01-24
ATE128459T1 (de) * 1990-02-07 1995-10-15 Nippon Shinyaku Co Ltd Sulfonanilidderivat und arzneimittel.
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
AU6003596A (en) * 1995-06-02 1996-12-18 Synaptic Pharmaceutical Corporation The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
WO2000010557A1 (fr) * 1998-08-25 2000-03-02 Nippon Shinyaku Co.,Ltd. Preparations solides stabilisees

Also Published As

Publication number Publication date
KR20030075173A (ko) 2003-09-22
SK9772003A3 (sk) 2005-03-04
WO2002060421A3 (en) 2002-12-19
CN1489459A (zh) 2004-04-14
HUP0302752A2 (hu) 2003-11-28
DE10104369A1 (de) 2002-08-08
EA200300789A1 (ru) 2004-02-26
DE60203882D1 (de) 2005-06-02
DE60203882T2 (de) 2006-02-02
MXPA03006816A (es) 2004-05-14
ES2240708T3 (es) 2005-10-16
CA2434565A1 (en) 2002-08-08
PL361731A1 (en) 2004-10-04
PT1363614E (pt) 2005-06-30
ZA200305201B (en) 2004-05-17
JP2004517158A (ja) 2004-06-10
EE200300357A (et) 2003-10-15
NO20033428L (no) 2003-09-30
BG108033A (en) 2004-12-30
WO2002060421A2 (en) 2002-08-08
CZ20032097A3 (cs) 2003-12-17
DK1363614T3 (da) 2005-05-30
EP1363614B1 (en) 2005-04-27
UY27145A1 (es) 2002-08-30
ATE293966T1 (de) 2005-05-15
IL156730A0 (en) 2004-02-08
EP1363614A2 (en) 2003-11-26
ECSP034684A (es) 2003-08-29
NO20033428D0 (no) 2003-07-31
BR0206854A (pt) 2004-01-13

Similar Documents

Publication Publication Date Title
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
SV2002000520A (es) Derivados de pirazol ref. pcs10927aajr/bb
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
BR0317715A (pt) Composições e processos de uso de collajolie
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
UY27740A1 (es) Nuevos compuestos
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
BR0309492A (pt) Uso de pelo menos um álcool ramificado alcoxilado
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
CO4940466A1 (es) Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
BR0317282A (pt) Derivados de 3h-quinazolin-4-ona
WO2002000183A3 (en) Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
BR0308762A (pt) Formulação farmacêutica compreendendo melatonina
BR0211784A (pt) Método para reduzir o crescimento capilar humano, uso de alfa-difluorometilornitina, e composição cosmética usada para a redução do crescimento capilar humano
AR035778A1 (es) Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil)etanol para tratar la incontinencia urinaria
HN1999000101A (es) Inhibidores de las fkbp.
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina

Legal Events

Date Code Title Description
FB Suspension of granting procedure